CRR_Call Tracker

Text/HTML

Text/HTML

ValueProductView

ValueProductPastPerformance

Company NameReco DateReco PriceExit PriceExit Date% ReturnIn days
ITC Ltd. 28/12/2023464.20487.5002/01/2025 5.02% 1 yrs
Britannia Industries Ltd. 27/07/20234,875.805,028.2512/11/2024 3.13% 1 yrs
JSW Steel Ltd. 22/02/2024826.951,003.0026/09/2024 21.29% 217 days
Bajaj Auto Ltd. 22/08/20249,910.0011,930.0017/09/2024 20.38% 26 days
Dr. Reddy's Laboratories Ltd. 26/10/20235,429.306,536.0005/07/2024 20.38% 253 days
Shriram Finance Ltd. 25/04/20242,430.102,955.0028/06/2024 21.60% 64 days
Coal India Ltd. 25/01/2024389.50501.6022/05/2024 28.78% 118 days
Infosys Ltd. 27/10/20221,522.601,411.6019/04/2024 -7.29% 1 yrs
State Bank Of India 25/05/2023581.30782.0505/03/2024 34.53% 285 days
The Indian Hotels Company Ltd. 24/08/2023401.85517.9007/02/2024 28.88% 167 days

CRR_MVC_PastPerformance

Text/HTML

Our Other Trader Products

EasyDNNNews

Aurobindo arm to acquire dermatology, oral solids businesses of Sandoz, US

Akshay N Gadiya 0 2913 Article rating: 4.0

Aurobindo Pharma Ltd's wholly-owned subsidiary, Aurobindo Pharma USA Incorporated signed a definitive agreement to acquire commercial operations and three manufacturing facilities related to dermatology and oral solids businesses in US from Sandoz Inc., USA, a Novartis Division.

Centrum to acquire supply chain business of L&T Finance

Akshay N Gadiya 0 2338 Article rating: 4.0

Centrum Financial Services Limited signed an agreement to acquire L&T Finance's Supply Chain Finance business on Wednesday. The supply chain vertical provides working capital finance to entities that are suppliers to large industrial manufacturers and Original Equipment Manufacturers (OEMs). The company also provide channel finance and inventory finance to dealers. Its combined customer base is nearly about 800.

Panacea Biotec inks tripartite agreement for Azacitidine injection in US market

Akshay N Gadiya 0 2981 Article rating: 5.0

Panacea Biotec Ltd. announced that it has entered into a tripartite agreement with Natco Pharma Ltd. and Breckenridge Pharmaceutical Inc. for the manufacture and supply of Azacitidine injection for the US market under Breckenridge's already-Approved New Drugs Application (ANDA).

Q1FY19 Result: Tata Investment Corporation reports 22 per cent Revenue growth

Akshay N Gadiya 0 2490 Article rating: 3.3

EBITDA for the quarter rose by 26.3 per cent yoy to Rs. 26.34 crore with a corresponding margin expansion of 282 bps. EBITDA margin for the quarter stood at 85.1 per cent. TICL functions on an invest and hold business model that has hardly any operating expenses and thus exceptional margins. The PAT for the quarter came in at Rs. 22.48 crore, yoy increase of 25 per cent.

RSS

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR